IL324569A - שימושים טיפוליים ומינונים של תרכובות משבשות lp(a) - Google Patents

שימושים טיפוליים ומינונים של תרכובות משבשות lp(a)

Info

Publication number
IL324569A
IL324569A IL324569A IL32456925A IL324569A IL 324569 A IL324569 A IL 324569A IL 324569 A IL324569 A IL 324569A IL 32456925 A IL32456925 A IL 32456925A IL 324569 A IL324569 A IL 324569A
Authority
IL
Israel
Prior art keywords
compound
individual
treatment
dose
pharmaceutically acceptable
Prior art date
Application number
IL324569A
Other languages
English (en)
Inventor
Shweta Urva
Original Assignee
Lilly Co Eli
Shweta Urva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Shweta Urva filed Critical Lilly Co Eli
Publication of IL324569A publication Critical patent/IL324569A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL324569A 2023-06-30 2024-06-27 שימושים טיפוליים ומינונים של תרכובות משבשות lp(a) IL324569A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363511209P 2023-06-30 2023-06-30
PCT/US2024/035698 WO2025006661A1 (en) 2023-06-30 2024-06-27 Therapeutic uses and doses of lp(a) disrupter compounds

Publications (1)

Publication Number Publication Date
IL324569A true IL324569A (he) 2026-01-01

Family

ID=91946802

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324569A IL324569A (he) 2023-06-30 2024-06-27 שימושים טיפוליים ומינונים של תרכובות משבשות lp(a)

Country Status (9)

Country Link
EP (1) EP4734986A1 (he)
JP (1) JP2026521235A (he)
KR (1) KR20260016529A (he)
CN (1) CN121443287A (he)
AU (1) AU2024308276A1 (he)
IL (1) IL324569A (he)
MX (1) MX2025015422A (he)
TW (1) TW202517250A (he)
WO (1) WO2025006661A1 (he)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102720992B1 (ko) 2019-06-07 2024-10-24 일라이 릴리 앤드 캄파니 피롤리딘 화합물

Also Published As

Publication number Publication date
EP4734986A1 (en) 2026-05-06
MX2025015422A (es) 2026-02-03
KR20260016529A (ko) 2026-02-03
AU2024308276A1 (en) 2025-11-13
JP2026521235A (ja) 2026-06-29
CN121443287A (zh) 2026-01-30
TW202517250A (zh) 2025-05-01
WO2025006661A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
O'Donoghue et al. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN (a) reduction-DOSE finding study (OCEAN (a)-DOSE)
JP7566815B2 (ja) プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法
US20240115708A1 (en) Dosing Regimens For The Treatment Of Fabry Disease
JP7830313B2 (ja) アルコール性肝炎の処置
US20140235670A1 (en) Treatment of progressive forms of multiple sclerosis with laquinimod
US20260027100A1 (en) Therapeutic tyrosine kinase inhibitors for myelin oligodendrocyte glycoprotein antibody disease (mogad)
WO2024006406A1 (en) Therapeutic tyrosine kinase inhibitors for multiple sclerosis and myasthenia gravis
TW202102220A (zh) 類鐸受體促效劑給藥方案
AU2019354784B2 (en) Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases
US20130267566A1 (en) Durable treatment with 4-aminopyridine in patients with demyelination
US20260014130A1 (en) Formulations of capsid inhibitor
WO2026050513A1 (en) Tolebrutinib for multiple sclerosis
WO2025006661A1 (en) Therapeutic uses and doses of lp(a) disrupter compounds
Kakuda et al. JNJ-64530440, a novel capsid assembly modulator: single-and multiple-ascending dose safety, tolerability and pharmacokinetics in healthy volunteers
KR20040058201A (ko) 치매전 상태에 사용되는 로수바스타틴
JP2023049008A (ja) １回当たりの投与量がイサブコナゾール換算で１００～４００ｍｇである、イサブコナゾール又はそのプロドラッグを有効成分として含有する製剤
HK40097424A (en) Use of alprostadil liposome in prevention and/or treatment of kidney injuries
KR20250108710A (ko) 다발성 경화증의 치료 방법
CA3268726A1 (en) Therapeutic tyrosine kinase inhibitors for multiple sclerosis
WO2025228863A1 (en) Dose regimen for a 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivative
CA3071096A1 (en) Co-administration of minocycline and colistin to reduce acute kidney injury
CN121693519A (zh) Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法
CN119522109A (zh) 用于钙调磷酸酶抑制剂的间歇性给药的组合物
WO2023151638A1 (zh) 前列地尔脂质体预防和/或治疗肾损伤的用途
Kymriah NEW DRUG APPROVALS